1. |
Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
|
2. |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin, 2017, 67(1): 7-30.
|
3. |
Banin Hirata BK, Oda JM, Losi Guembarovski R, et al. Molecular markers for breast cancer: prediction on tumor behavior. Dis Markers, 2014, 2014: 513158.
|
4. |
van’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature, 2002, 415(6871): 530-536.
|
5. |
Ivshina AV, George J, Senko O, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res, 2006, 66(21): 10292-10301.
|
6. |
Lips EH, Michaut M, Hoogstraat M, et al. Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response. Breast Cancer Res, 2015, 17(1): 134.
|
7. |
Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumours of the breast. Lyon: IABC Press, 2012: 13-15.
|
8. |
Almendro V, Fuster G. Heterogeneity of breast cancer: etiology and clinical relevance. Clin Transl Oncol, 2011, 13(11): 767-773.
|
9. |
Ariga R, Zarif A, Korasick J, et al. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J, 2005, 11(4): 278-280.
|
10. |
徐倩倩, 王常珺, 孙强. 三阴性乳腺癌分子分型与个体化靶向治疗现状. 中华肿瘤防治杂志, 2017, 24(11): 788-794.
|
11. |
Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med, 2004, 351(27): 2817-2826.
|
12. |
Kataoka Y, Mukohara T, Shimada H, et al. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol, 2010, 21(2): 255-262.
|
13. |
袁鹏飞, 汪建光, 张丽柯, 等. PIK3CA 基因在乳腺癌不同分子亚型中突变的研究. 河南科技大学学报: 医学版, 2014, 32(4): 245-246, 250.
|
14. |
Bhat-Nakshatri P, Goswami CP, Badve S, et al. Molecular insights of pathways resulting from two common PIK3CA mutations in breast cancer. Cancer Res, 2016, 76(13): 3989-4001.
|
15. |
von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol, 2014, 15(7): 747-756.
|
16. |
Kalinsky K, Jacks LM, Heguy A, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res, 2009, 15(16): 5049-5059.
|
17. |
李少英, 王维, 李建梅, 等. PIK3CA 基因突变与乳腺癌恶性程度和预后的关系. 中华肿瘤杂志, 2011, 33(8): 605-608.
|
18. |
Park BH, Davidson NE. PI3 kinase activation and response to trastuzumab therapy: what’s neu with herceptin resistance? Cancer Cell, 2007, 12(4): 297-299.
|
19. |
Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell, 2007, 12(4): 395-402.
|
20. |
邓粤敏, 徐韫健. PIK3CA 基因突变状态在乳腺癌不同临床病理特征中的研究. 国际检验医学杂志, 2016, 37(15): 2110-2111, 2114.
|
21. |
Lalloo F, Varley J, Moran A, et al. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer, 2006, 42(8): 1143-1150.
|
22. |
樊菁, 吕勇刚, 王廷, 等. 易感基因突变与遗传性乳腺癌的关系. 中华乳腺病杂志: 电子版, 2014, 8(6): 34-42.
|
23. |
Lee DS, Yoon SY, Looi LM, et al. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. Breast Cancer Res, 2012, 14(2): R66.
|
24. |
Mouchawar J, Korch C, Byers T, et al. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res, 2010, 70(12): 4795-4800.
|
25. |
杨晓晨, 胡震, 吴炅, 等. 中国乳腺癌高风险人群中 TP53 基因胚系突变的研究. 中华医学遗传学杂志, 2015, 32(6): 761-765.
|